Canaccord Genuity Group set a C$12.50 price objective on Cipher Pharmaceuticals (TSE:CPH – Free Report) (NASDAQ:CPHR) in a report published on Monday,BayStreet.CA reports. The firm currently has a hold rating on the stock.
Cipher Pharmaceuticals Trading Up 5.0 %
Cipher Pharmaceuticals stock opened at C$11.76 on Monday. Cipher Pharmaceuticals has a 52 week low of C$8.01 and a 52 week high of C$19.69. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. The firm has a market capitalization of C$211.13 million, a price-to-earnings ratio of 12.99 and a beta of 1.20. The company has a 50 day moving average price of C$12.41 and a 200 day moving average price of C$14.02.
Insiders Place Their Bets
In other news, Director Harold Morton Wolkin sold 3,500 shares of Cipher Pharmaceuticals stock in a transaction dated Monday, March 24th. The stock was sold at an average price of C$13.49, for a total transaction of C$47,215.00. Corporate insiders own 42.00% of the company’s stock.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
See Also
- Five stocks we like better than Cipher Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- 3 Best Fintech Stocks for a Portfolio Boost
- Are Tariffs Threatening Disney’s Comeback Story?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
